City of Hope, Cellares collaborate to automate manufacturing of solid tumor CAR T-cell therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cellares and City of Hope announced a collaboration to evaluate automated manufacturing of City of Hope’s investigational gene-modified CAR T-cell therapy targeting glioblastoma multiforme, an aggressive solid tumor brain cancer with limited treatment options.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login